Gain Therapeutics, Inc. (NASDAQ:GANX) Stock Has Consensus Target Price of $7.50

Shares of Gain Therapeutics, Inc. (NASDAQ:GANX) have been assigned an average rating of “Moderate Buy” from the five brokerages that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating and four have given a buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $7.67.

A number of research analysts recently weighed in on the company. Wall Street Zen raised Gain Therapeutics from a “strong sell” rating to a “sell” rating in a report on Sunday, June 21st. BTIG Research reaffirmed a “buy” rating and set a $5.00 price objective on shares of Gain Therapeutics in a research report on Monday. Weiss Ratings reiterated a “sell (e+)” rating on shares of Gain Therapeutics in a report on Friday, September 4th. Finally, HC Wainwright reiterated a “buy” rating and issued a $8.00 price objective on shares of Gain Therapeutics in a report on Monday.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Squarepoint Ops LLC acquired a new stake in Gain Therapeutics during the second quarter worth approximately $277,000. HighTower Advisors LLC acquired a new position in shares of Gain Therapeutics in the second quarter valued at approximately $35,000. HB Wealth Management LLC bought a new position in shares of Gain Therapeutics during the second quarter worth approximately $26,000. Two Sigma Securities LLC acquired a new stake in Gain Therapeutics during the 2nd quarter worth approximately $26,000. Finally, BlackRock Inc. acquired a new stake in Gain Therapeutics during the 2nd quarter worth approximately $558,000. Institutional investors and hedge funds own 11.97% of the company’s stock.

Gain Therapeutics Trading Down 3.3%

Gain Therapeutics stock opened at $1.61 on Friday. The stock has a 50-day simple moving average of $1.83 and a 200 day simple moving average of $1.83. The stock has a market capitalization of $70.48 million, a P/E ratio of -3.23 and a beta of 0.19. The company has a debt-to-equity ratio of 0.02, a quick ratio of 4.36 and a current ratio of 4.36. Gain Therapeutics has a 52 week low of $1.53 and a 52 week high of $4.34.

Gain Therapeutics (NASDAQ:GANX) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.03. Analysts expect that Gain Therapeutics will post -0.5 earnings per share for the current year.

Gain Therapeutics Company Profile

Gain Therapeutics, Inc is a clinical-stage biotechnology company developing small-molecule therapies for neurodegenerative diseases and lysosomal storage disorders. Its research focuses on correcting the activity of misfolded or dysfunctional lysosomal enzymes, which are implicated in conditions involving the accumulation of toxic cellular material.

The company uses a structure-based drug discovery platform designed to identify previously unrecognized binding sites on disease-related proteins.